Quantinno Capital Management LP Trims Stock Holdings in Organon & Co. $OGN

Quantinno Capital Management LP lowered its holdings in Organon & Co. (NYSE:OGN) by 27.1% during the 1st quarter, HoldingsChannel.com reports. The firm owned 265,024 shares of the company’s stock after selling 98,466 shares during the quarter. Quantinno Capital Management LP’s holdings in Organon & Co. were worth $1,587,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Private Management Group Inc. boosted its stake in Organon & Co. by 38.3% during the 4th quarter. Private Management Group Inc. now owns 4,347,073 shares of the company’s stock valued at $31,169,000 after purchasing an additional 1,204,979 shares during the period. UBS Group AG grew its position in Organon & Co. by 55.2% in the 4th quarter. UBS Group AG now owns 4,295,002 shares of the company’s stock worth $30,795,000 after purchasing an additional 1,527,492 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Organon & Co. by 2.7% in the fourth quarter. Vanguard Group Inc. now owns 36,916,382 shares of the company’s stock valued at $264,690,000 after purchasing an additional 987,979 shares during the period. Brandes Investment Partners LP increased its stake in shares of Organon & Co. by 46.7% in the fourth quarter. Brandes Investment Partners LP now owns 606,499 shares of the company’s stock valued at $4,349,000 after purchasing an additional 193,064 shares during the period. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al raised its holdings in shares of Organon & Co. by 1,062.1% during the fourth quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 254,500 shares of the company’s stock valued at $1,825,000 after buying an additional 232,600 shares during the last quarter. 77.43% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

OGN has been the subject of several analyst reports. BNP Paribas Exane reiterated a “neutral” rating and set a $14.00 price objective (up from $12.00) on shares of Organon & Co. in a research report on Wednesday, April 29th. Piper Sandler raised Organon & Co. from an “underweight” rating to a “neutral” rating and lifted their target price for the company from $5.00 to $14.00 in a research note on Tuesday, April 28th. Finally, Weiss Ratings lowered Organon & Co. from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, August 3rd. Five investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and a consensus price target of $11.40.

Organon & Co. Stock Performance

Shares of OGN opened at $13.66 on Thursday. The firm has a market capitalization of $3.59 billion, a PE ratio of 17.74, a P/E/G ratio of 1.26 and a beta of 1.55. The company has a quick ratio of 1.44, a current ratio of 1.95 and a debt-to-equity ratio of 8.43. The firm has a 50-day moving average price of $13.51 and a 200 day moving average price of $10.68. Organon & Co. has a 52-week low of $5.69 and a 52-week high of $13.70.

Organon & Co. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a dividend of $0.02 per share. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Organon & Co.’s dividend payout ratio (DPR) is currently 10.39%.

Organon & Co. Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.